Skip to main navigation Skip to search Skip to main content

Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up

  • Alexander J. Stratigos
  • , Aleksandar Sekulic
  • , Ketty Peris
  • , Oliver Bechter
  • , Sorilla Prey
  • , Karl D. Lewis
  • , Nicole Basset-Seguin
  • , Anne Lynn S. Chang
  • , Stéphane Dalle
  • , Almudena Fernández Orland
  • , Lisa Licitra
  • , Caroline Robert
  • , Claas Ulrich
  • , Axel Hauschild
  • , Michael R. Migden
  • , Reinhard Dummer
  • , Suk Young Yoo
  • , Emmanuel Okoye
  • , Ioannis Bassukas
  • , Carmen Loquai
  • Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Timothy J. Inocencio, Chieh I. Chen, Patrick R. LaFontaine, Frank Seebach, Israel Lowy, Matthew G. Fury

Research output: Contribution to journalArticlepeer-review

16 Scopus citations
Original languageEnglish
Pages (from-to)414-418
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume90
Issue number2
DOIs
StatePublished - Feb 2024
Externally publishedYes

Keywords

  • cemiplimab
  • clinical trial
  • hedgehog inhibitor
  • immune checkpoint inhibitor
  • locally advanced basal cell carcinoma
  • phase 2
  • quality of life

Cite this